OPEN END TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 01:29:44 2024-05-21 pm EDT | ||
| 20.11 EUR | -3.87% |
|
| Current month | +22.25% | ||
| 1 month | +20.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 20.11 | -3.87% |
| 24-05-20 | 20.92 | +1.80% |
| 24-05-17 | 20.55 | +2.39% |
| 24-05-16 | 20.07 | -0.35% |
| 24-05-15 | 20.14 | +6.39% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 01:29 pm EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KF61CY |
| ISIN | DE000KF61CY1 |
| Date issued | 2021-12-03 |
| Strike | 221.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.93 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.46 € |
|---|---|
| Lowest since issue | 1.91 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
442
USD
Average target price
462.8
USD
Spread / Average Target
+4.71%
- Stock Market
- Certificates
- Certificat
